(Gatipotuzumab)Biosimilar Reference Antibody-GS40295 新品

货号：GS40295

Gatipotuzumab is an investigational, humanized monoclonal antibody developed for the treatment of solid tumors, with a focus on adenocarcinomas such as ovarian, breast, and endometrial cancers. It represents a novel approach due to its unique target specificity. Gatipotuzumab is engineered to recognize a specific tumor-associated glycoform of the MUC1 glycoprotein. By binding with high affinity to this aberrantly glycosylated form of MUC1, which is selectively expressed on cancer cells, the antibody aims to direct immune-mediated killing specifically to the tumor. Its proposed mechanisms of action include antibody-dependent cellular cytotoxicity (ADCC) and potentially the inhibition of tumor-promoting signaling pathways.